Program
carfilzomib
Also written as “Carfilzomib”, “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)” and “Drug: Carfilzomib + Dexamethasone”.
Its studies are mostly in Multiple Myeloma · Amyloidosis · Small Cell Lung Carcinoma · Waldenstrom Macroglobulinemia · Hematologic Neoplasms, led by 5 companies.
Drug pageCarfilzomib: every studyMany companies study it; this page follows only the 33 they lead. All 157 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 230 open or running | phase 4since Apr 16, 2019 | Sep 6, 2005 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Sep 27, 2013 | Jun 2027phase 2 · NCT02899052 |
| Criteriumits history only | 30 open or running | phase 2since Oct 19, 2011 | Oct 19, 2011 | none ahead |
| Oncotherapeuticsits history only | 20 open or running | phase 2since Jan 3, 2013 | Jan 3, 2013 | none ahead |
| Sanofiits history only | 22 open or running | phase 2since Jan 20, 2023 | Jan 20, 2023 | Apr 1, 2027phase 2 · NCT06356571 |
Also a collaborator on its studies: Bristol-Myers Squibb and Onyx Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Amgen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Sep 6, 2005.
- Feb 10, 2011Phase 3 study in Multiple MyelomaNCT01302392 · 315 enrolled · Australia, Austria, Belgium and more
- Mar 28, 2012Phase 3 study in Multiple MyelomaNCT01568866 · 929 enrolled · United States, Australia, Austria and more
- Aug 30, 2012Phase 2 study in Multiple MyelomaNCT01677858 · 116 enrolled · United States
- Feb 12, 2013Phase 3 study in Multiple MyelomaNCT01818752 · 955 enrolled · United States, Argentina, Australia and more
- Sep 6, 20132 phase 1 studiesNCT01949545, NCT01949532
- Oct 28, 2013Phase 1 study in Multiple MyelomaNCT01980589 · 22 enrolled · United States
- Nov 6, 2013Phase 2 study in Small Cell Lung CarcinomaNCT01987232 · 32 enrolled · United States, Canada, Russian Federation
- Dec 23, 2014Phase 1 study in Multiple MyelomaNCT02335983 · 107 enrolled · United States
- Apr 6, 2015Phase 3 study in Multiple MyelomaNCT02412878 · 478 enrolled · United States, Australia, Belgium and more
- Nov 11, 2016Phase 3 study in RecurrenceNCT03029234 · 126 enrolled · China
- Apr 2, 2018Phase 2 study in RecurrenceNCT03512353 · 7 enrolled · United States
- Jan 14, 2019Phase 3 study in RecurrenceNCT03859427 · 454 enrolled · United States, Austria, Bulgaria and more
- Apr 16, 2019Phase 4 study in Multiple MyelomaNCT03934684 · 101 enrolled · India
- Nov 22, 2019Phase 2 study in RecurrenceNCT04191616 · 54 enrolled · United States, Denmark, Estonia and more
TargetBeta
“26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bortezomibrule | Johnson & Johnson | phase 4 | 85 |
Studies
All 23 Amgen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04191616Recurrence · United States, Denmark, Estonia and more | 2 | Completed | Nov 30, 2022 | 54 |
| NCT03934684Multiple Myeloma · India | 4 | Completed | Mar 23, 2023 | 101 |
| NCT03859427Recurrence · United States, Austria, Bulgaria and more | 3 | Completed | Mar 31, 2023 | 454 |
| NCT03512353Recurrence · United States | 2 | Terminated | Jan 16, 2020 | 7 |
| NCT03029234Recurrence · China | 3 | Completed | Nov 5, 2018 | 126 |
| NCT02412878Multiple Myeloma · United States, Australia, Belgium and more | 3 | Completed | Jun 15, 2017 | 478 |
| NCT02335983Multiple Myeloma · United States | 1 | Completed | Oct 28, 2019 | 107 |
| NCT01987232Small Cell Lung Carcinoma · United States, Canada, Russian Federation | 2 | Completed | Aug 2016 | 32 |
| NCT01980589Multiple Myeloma · United States | 1 | Completed | Mar 2016 | 22 |
| NCT01949545Hematologic Neoplasms · United States, France, Netherlands and more | 1 | Completed | Aug 2015 | 46 |
| NCT01949532Multiple Myeloma · United States, Australia, Canada | 1 | Completed | Apr 2015 | 26 |
| NCT01818752Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | Jul 15, 2016 | 955 |
| NCT01677858Multiple Myeloma · United States | 2 | Completed | Jul 22, 2016 | 116 |
| NCT01568866Multiple Myeloma · United States, Australia, Austria and more | 3 | Completed | Nov 10, 2014 | 929 |
| NCT01302392Multiple Myeloma · Australia, Austria, Belgium and more | 3 | Completed | Jul 2014 | 315 |
| NCT01080391Multiple Myeloma · United States, Austria, Belgium and more | 3 | Completed | Jun 16, 2014 | 792 |
| NCT00884312Multiple Myeloma · United States, Canada | 2 | Completed | May 17, 2017 | 101 |
| NCT00721734Multiple Myeloma · United States | 2 | Completed | Nov 2012 | 50 |
| NCT00603447Multiple Myeloma · United States, Canada | 1 | Completed | May 2013 | 84 |
| NCT00531284Ovarian Neoplasms · United States | 2 | Completed | Oct 2014 | 184 |
| NCT00530816Multiple Myeloma · United States, Canada | 2 | Completed | Jan 2013 | 164 |
| NCT00511238Multiple Myeloma · United States, Canada | 2 | Completed | Nov 2010 | 312 |
| NCT00150462Waldenstrom Macroglobulinemia · United States | 1 | Completed | Oct 2009 | 48 |
How it is read
Names in the registry
- “Carfilzomib”, 34 entries
- “carfilzomib”, 3 entries
- “Cohort C1 & C2: KTX-1001 + Carfilzomib (KYPROLIS®)”, 1 entry
- “Drug: Carfilzomib + Dexamethasone”, 1 entry
- “Drug: Carfilzomib + Lenalidomide + Dexamethasone”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 33 studies
- Amyloidosis, 1 study
- Small Cell Lung Carcinoma, 1 study
- Waldenstrom Macroglobulinemia, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.